Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MUSTANG BIO, INC.

Get SEC filing alerts via email and in your feed for MUSTANG BIO, INC.

MBIO

MUSTANG BIO, INC.

About MUSTANG BIO, INC.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company developing innovative cell therapies, primarily CAR T treatments for cancers and autoimmune diseases. Its pipeline includes therapies targeting glioblastoma, hematologic malignancies, and autoimmune conditions, often in partnership with leading research institutions. The company focuses on licensing advanced technologies, supporting clinical trials, and commercializing targeted immunotherapies to address unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MUSTANG BIO, INC.

1
1
MUSTANG BIO, INC. Mustang Bio Reports $955,000 Net Loss in Q1 2026, Focuses on Novel Cancer Therapies

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
MUSTANG BIO, INC. Mustang Bio Reports Reduced Net Loss and Increased Cash Reserves in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
MUSTANG BIO, INC. Mustang Bio Reports Significant Reduction in Net Loss and Operating Expenses for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
MUSTANG BIO, INC. Mustang Bio Reports $153,000 Net Loss in Q1 2025, Significant Improvement from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
MUSTANG BIO, INC. Mustang Bio Reports Significant Reduction in Operating Expenses, Net Loss Improves in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments